Generative artificial intelligence in drug discovery: basic framework, recent advances, challenges, and opportunities
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
There are two main ways to discover or design small drug molecules. The first involves fine-tuning existing molecules or commercially successful drugs through quantitative structure-activity relationships and virtual screening. The second approach involves generating new molecules through de novo drug design or inverse quantitative structure-activity relationship. Both methods aim to get a drug molecule with the best pharmacokinetic and pharmacodynamic profiles. However, bringing a new drug to market is an expensive and time-consuming endeavor, with the average cost being estimated at around $2.5 billion. One of the biggest challenges is screening the vast number of potential drug candidates to find one that is both safe and effective. The development of artificial intelligence in recent years has been phenomenal, ushering in a revolution in many fields. The field of pharmaceutical sciences has also significantly benefited from multiple applications of artificial intelligence, especially drug discovery projects. Artificial intelligence models are finding use in molecular property prediction, molecule generation, virtual screening, synthesis planning, repurposing, among others. Lately, generative artificial intelligence has gained popularity across domains for its ability to generate entirely new data, such as images, sentences, audios, videos, novel chemical molecules, etc. Generative artificial intelligence has also delivered promising results in drug discovery and development. This review article delves into the fundamentals and framework of various generative artificial intelligence models in the context of drug discovery via de novo drug design approach. Various basic and advanced models have been discussed, along with their recent applications. The review also explores recent examples and advances in the generative artificial intelligence approach, as well as the challenges and ongoing efforts to fully harness the potential of generative artificial intelligence in generating novel drug molecules in a faster and more affordable manner. Some clinical-level assets generated form generative artificial intelligence have also been discussed in this review to show the ever-increasing application of artificial intelligence in drug discovery through commercial partnerships.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deep Residual Learning for Image Recognition
He, K., Zhang, X., Ren, S., & Sun, J. (2016) · 2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR) · doi:10.1109/cvpr.2016.90 · Cited by 235,474
Hochreiter, S., & Schmidhuber, J. (1997) · Neural Computation · doi:10.1162/neco.1997.9.8.1735 · Cited by 102,318
LeCun, Y., Bengio, Y., & Hinton, G. (2015) · Nature · doi:10.1038/nature14539 · Cited by 84,126
VMD: visual molecular dynamics
Humphrey, W., Dalke, A., & Schulten, K. (1996) · Journal of Molecular Graphics · doi:10.1016/0263-7855(96)00018-5 · Cited by 66,952
Gradient-based learning applied to document recognition
Lecun, Y., Bottou, L., Bengio, Y., & Haffner, P. (1998) · Proceedings of the IEEE · doi:10.1109/5.726791 · Cited by 58,805
Squeeze-and-Excitation Networks
Hu, J., Shen, L., & Sun, G. (2018) · 2018 IEEE/CVF Conference on Computer Vision and Pattern Recognition · doi:10.1109/cvpr.2018.00745 · Cited by 35,667
On Information and Sufficiency
Kullback, S., & Leibler, R. A. (1951) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177729694 · Cited by 20,193
Generative adversarial networks
Goodfellow, I., Pouget-Abadie, J., Mirza, M., Xu, B., Warde-Farley, D., Ozair, S., Courville, A., & Bengio, Y. (2020) · Communications of the ACM · doi:10.1145/3422622 · Cited by 18,384
Squeeze-and-Excitation Networks
Hu, J., Shen, L., Albanie, S., Sun, G., & Wu, E. (2020) · IEEE Transactions on Pattern Analysis and Machine Intelligence · doi:10.1109/tpami.2019.2913372 · Cited by 12,157
Weininger, D. (1988) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci00057a005 · Cited by 7,436 · cited 2×
“Simpli fi ed Molecular Input Line Entry Systems (SMILES (Weininger, 1988)), strings are an example of a string notation that enables this.”
Background3D Convolutional Neural Networks for Human Action Recognition
Ji, S., Xu, W., Yang, M., & Yu, K. (2013) · IEEE Transactions on Pattern Analysis and Machine Intelligence · doi:10.1109/tpami.2012.59 · Cited by 6,235
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359 · cited 1×
“The pharmaceutical sector is seeing a decline in productivity as the cost of developing and bringing a new medicine to market continues to rise (Paul et al., 2010; DiMasi et al., 2016).”
BackgroundAutomatic Chemical Design Using a Data-Driven Continuous Representation of Molecules
Gómez-Bombarelli, R., Wei, J. N., Duvenaud, D., Hernández-Lobato, J. M., Sánchez-Lengeling, B., Sheberla, D., Aguilera-Iparraguirre, J., Hirzel, T. D., Adams, R. P., & Aspuru-Guzik, A. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00572 · Cited by 3,106
The Vanishing Gradient Problem During Learning Recurrent Neural Nets and Problem Solutions
Hochreiter, S. (1998) · International Journal of Uncertainty, Fuzziness and Knowledge-Based Systems · doi:10.1142/s0218488598000094 · Cited by 2,939
A Deep Learning Approach to Antibiotic Discovery
Stokes, J. M., Yang, K., Swanson, K., Jin, W., Cubillos-Ruiz, A., Donghia, N. M., MacNair, C. R., French, S., Carfrae, L. A., Bloom-Ackermann, Z., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.021 · Cited by 2,463 · cited 1×
“For instance, Stokes et al. (Stokes et al., 2020), used a deep neural network based on molecular graphs to predict antibiotic activity in compounds structurally distinct from known antibiotics and then validated it in experiments.”
BackgroundDeep learning enables rapid identification of potent DDR1 kinase inhibitors
Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., Terentiev, V. A., Polykovskiy, D. A., Kuznetsov, M. D., Asadulaev, A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0224-x · Cited by 1,573
Generating Focused Molecule Libraries for Drug Discovery with Recurrent Neural Networks
Segler, M. H. S., Kogej, T., Tyrchan, C., & Waller, M. P. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00512 · Cited by 1,537
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E., & Stebbing, J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30304-4 · Cited by 1,456
ChatGPT and other large language models are double-edged swords
Shen, Y., Heacock, L., Elias, J., Hentel, K. D., Reig, B., Shih, G., & Moy, L. (2023) · Radiology · doi:10.1148/radiol.230163 · Cited by 1,008
Ultra-large library docking for discovering new chemotypes
Lyu, J., Wang, S., Balius, T. E., Singh, I., Levit, A., Moroz, Y. S., O’Meara, M. J., Che, T., Algaa, E., Tolmachova, K., et al. (2019) · Nature · doi:10.1038/s41586-019-0917-9 · Cited by 998
Distributed Prioritized Experience Replay
Horgan, D., Quan, J., Budden, D., Barth-Maron, G., Hessel, M., van Hasselt, H., & Silver, D. (2018) · arXiv · doi:10.48550/arxiv.1803.00933 · Cited by 963
The PDBbind database: methodologies and updates
Wang, R., Fang, X., Lu, Y., Yang, C.-Y., & Wang, S. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm048957q · Cited by 933 · cited 1×
“…can take 1D or 2D molecular structure data and output it as a random 3D molecular conformation, the actual 3D structure of the molecule, which may be connected to a molecular feature like the IC50 of a particular target, would be lost in the process (Sussman et al., 1998; Wang et al., 2005).”
BackgroundSchneider, G. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.232 · Cited by 910 · cited 2×
“Rapidly navigating the chemical space using GAI models will be possible in the future with the help of self-driving laboratories (Schneider, 2018).”
BackgroundMethodGuacaMol: Benchmarking Models for de Novo Molecular Design
Brown, N., Fiscato, M., Segler, M. H. S., & Vaucher, A. C. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00839 · Cited by 895
Molecular Sets (MOSES): A Benchmarking Platform for Molecular Generation Models
Polykovskiy, D., Zhebrak, A., Sanchez-Lengeling, B., Golovanov, S., Tatanov, O., Belyaev, S., Kurbanov, R., Artamonov, A., Aladinskiy, V., Veselov, M., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.565644 · Cited by 849
What ChatGPT and generative AI mean for science
Stokel-Walker, C., & Van Noorden, R. (2023) · Nature · doi:10.1038/d41586-023-00340-6 · Cited by 828
Applications of Deep Learning in Biomedicine
Mamoshina, P., Vieira, A., Lane, E., & Zhavoronkov, A. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00982 · Cited by 701
Reporting of artificial intelligence prediction models
Collins, G. S., & Moons, K. G. M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30037-6 · Cited by 701
Deep learning for molecular design—a review of the state of the art
Elton, D. C., Boukouvalas, Z., Fuge, M. D., & Chung, P. W. (2019) · Molecular Systems Design & Engineering · doi:10.1039/c9me00039a · Cited by 683
Tools such as ChatGPT threaten transparent science; here are our ground rules for their use
(2023) · Nature · doi:10.1038/d41586-023-00191-1 · Cited by 605
Kadurin, A., Nikolenko, S., Khrabrov, K., Aliper, A., & Zhavoronkov, A. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00346 · Cited by 587
Molecular representations in AI-driven drug discovery: a review and practical guide
David, L., Thakkar, A., Mercado, R., & Engkvist, O. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00460-5 · Cited by 587
REINVENT 2.0: An AI Tool for De Novo Drug Design
Blaschke, T., Arús-Pous, J., Chen, H., Margreitter, C., Tyrchan, C., Engkvist, O., Papadopoulos, K., & Patronov, A. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00915 · Cited by 496 · cited 1×
“Resemblance to existing active compounds, projected bioactivity, and estimated physicochemical attributes are often used scoring systems (Olivecrona et al., 2017; Blaschke et al., 2020).”
BackgroundCoeckelbergh, M. (2020) · Science and Engineering Ethics · doi:10.1007/s11948-019-00146-8 · Cited by 475 · cited 1×
“…and novel and improved deep learning (DL) algorithms have increased the success of arti fi cial intelligence (AI) in numerous areas, including computer vision, autonomous vehicles, robotics, and others (von Ungern-Sternberg, 2017; Coeckelbergh, 2020; Thierer et al., 2017; Collins and Moons, 2019).”
BackgroundMolGAN: An implicit generative model for small molecular graphs
De Cao, N., & Kipf, T. (2018) · arXiv · doi:10.48550/arxiv.1805.11973 · Cited by 442
Application of Generative Autoencoder in De Novo Molecular Design
Blaschke, T., Olivecrona, M., Engkvist, O., Bajorath, J., & Chen, H. (2018) · Molecular Informatics · doi:10.1002/minf.201700123 · Cited by 411
Bender, A., & Cortés-Ciriano, I. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.12.009 · Cited by 405
De Novo Design of Bioactive Small Molecules by Artificial Intelligence
Merk, D., Friedrich, L., Grisoni, F., & Schneider, G. (2018) · Molecular Informatics · doi:10.1002/minf.201700153 · Cited by 373
Ren, F., Ding, X., Zheng, M., Korzinkin, M., Cai, X., Zhu, W., Mantsyzov, A., Aliper, A., Aladinskiy, V., Cao, Z., et al. (2023) · Chemical Science · doi:10.1039/d2sc05709c · Cited by 365
Exposing the Limitations of Molecular Machine Learning with Activity Cliffs
van Tilborg, D., Alenicheva, A., & Grisoni, F. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01073 · Cited by 337 · cited 1×
“Although automated synthesis platforms may restrict the chemical space available for synthesis, they may be a viable alternative to speed up de novo design driven by GAI (van Tilborg et al., 2022).”
MethodEntangled Conditional Adversarial Autoencoder for de Novo Drug Discovery
Polykovskiy, D., Zhebrak, A., Vetrov, D., Ivanenkov, Y., Aladinskiy, V., Mamoshina, P., Bozdaganyan, M., Aliper, A., Zhavoronkov, A., & Kadurin, A. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00839 · Cited by 278
Health, T. L. D. (2023) · The Lancet Digital Health · doi:10.1016/s2589-7500(23)00023-7 · Cited by 257
The Evolution of Computing: AlphaGo
Chen, J. X. (2016) · Computing in Science & Engineering · doi:10.1109/mcse.2016.74 · Cited by 237 · cited 1×
“The method may be used for various settings and issues (Chen, 2016; Li and Du, 2018; Zhu et al., 2018; Holcomb et al., 2019; Vázquez-Canteli and Nagy, 2019).”
MethodShape-Based Generative Modeling for de Novo Drug Design
Skalic, M., Jiménez, J., Sabbadin, D., & De Fabritiis, G. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00706 · Cited by 229
AI in small-molecule drug discovery: a coming wave?
Jayatunga, M. K. P., Xie, W., Ruder, L., Schulze, U., & Meier, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/d41573-022-00025-1 · Cited by 187
Bai, Q., Liu, S., Tian, Y., Xu, T., Banegas‐Luna, A. J., Pérez‐Sánchez, H., Huang, J., Liu, H., & Yao, X. (2022) · WIREs Computational Molecular Science · doi:10.1002/wcms.1581 · Cited by 156 · cited 1×
“Various models, including DeepDTA, Pafnucy, OnionNet, AttentionDTA, and GraphDTA, use deep CNNs and attention mechanisms to achieve precise binding af fi nity predictions between drugs and targets (Bai et al., 2022).”
MethodDeep Reinforcement Learning for Mobile Edge Caching: Review, New Features, and Open Issues
Zhu, H., Cao, Y., Wang, W., Jiang, T., & Jin, S. (2018) · IEEE Network · doi:10.1109/mnet.2018.1800109 · Cited by 153 · cited 1×
“The method may be used for various settings and issues (Chen, 2016; Li and Du, 2018; Zhu et al., 2018; Holcomb et al., 2019; Vázquez-Canteli and Nagy, 2019).”
MethodDeepDrug3D: Classification of ligand-binding pockets in proteins with a convolutional neural network
Pu, L., Govindaraj, R. G., Lemoine, J. M., Wu, H.-C., & Brylinski, M. (2019) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006718 · Cited by 133
Cited by
A review of large language models and autonomous agents in chemistry
Ramos, M. C., Collison, C. J., & White, A. D. (2025) · Chemical Science · doi:10.1039/d4sc03921a · Cited by 274
Large Language Models in Healthcare and Medical Applications: A Review
Maity, S., & Saikia, M. J. (2025) · Bioengineering · doi:10.3390/bioengineering12060631 · Cited by 249
“By leveraging their pattern recognition abilities, LLMs can suggest novel molecular configurations that might address specific therapeutic targets, potentially expanding the range of treatment options for various conditions [4,51–54].”
Application of Artificial Intelligence In Drug-target Interactions Prediction: A Review
Liao, Q., Zhang, Y., Chu, Y., Ding, Y., Liu, Z., Zhao, X., Wang, Y., Wan, J., Ding, Y., Tiwari, P., et al. (2025) · npj Biomedical Innovations · doi:10.1038/s44385-024-00003-9 · Cited by 82
Metadata
- Authors
- Gangwal, A., Ansari, A., Ahmad, I., Azad, A. K., Kumarasamy, V., Subramaniyan, V., & Wong, L. S.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2024-02-07
- Volume
- 15
- Pages
- 1331062-1331062
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W4391610180
- Cited by
- 189
- References
- 49
- FWCI
- 37.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.